KKR settles US antitrust case accusing it of merger filing violations for $250 million


By Fabiola Arámburo and Mrinmay Dey

Aug 26 (Reuters) – KKR has agreed to pay $250 million to settle a U.S. antitrust ‌case which accused the private equity giant of repeatedly ‌violating federal premerger filing requirements and evading antitrust scrutiny in at least 16 transactions.

The ​U.S. Department of Justice said on Wednesday that the civil penalty was the largest-ever imposed for violations of the Hart-Scott-Rodino Antitrust Improvements Act, which requires companies to notify antitrust regulators of certain mergers ‌and acquisitions before they ⁠are completed.

KKR said in a statement that it had agreed to settle the case but strongly disagreed ⁠with the Justice Department’s characterization of the matter, adding: “We believe that our firm acted in good faith at all times under our prior ​filing ​process, and it was consistent with ​industry practice.”

It said the ‌penalty would have no financial impact on KKR, its funds or investors because it would be fully reimbursed by outside law firms.

The civil lawsuit was filed in 2025. Both the Biden and Trump administrations have sought to scrutinise merger activity and compliance with merger-review ‌rules.

The Justice Department said KKR, one ​of the world’s largest private equity ​firms with over $700 billion in ​assets under management, had made more than 100 ‌premerger filings since 2021 and was ​familiar with the ​law’s requirements.

Associate Attorney General Stanley Woodward said the settlement “sends a powerful message: the Department is committed to vigorous enforcement.”

The ​settlement was filed with ‌the U.S. District Court for the Southern District of ​New York.

(Reporting by Fabiola Arámburo and Mrinmay Dey in ​Mexico City; Editing by Edwina Gibbs)



Source link

  • Related Posts

    DMG Blockchain Solutions Reports Third Quarter 2026 Financial Results

    Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such information can generally be identified by the…

    Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

    Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. With our outstanding capacity for…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Sandra Bullock Makes the T-Strap Fall Shoe Trend Feel Fresh Again

    Sandra Bullock Makes the T-Strap Fall Shoe Trend Feel Fresh Again

    Nova Scotia’s new welfare rules exclude tents, cars and trailers

    Nova Scotia’s new welfare rules exclude tents, cars and trailers

    DMG Blockchain Solutions Reports Third Quarter 2026 Financial Results

    Why Is The Mac Mini M5 Pro More Expensive Than The M6?

    Why Is The Mac Mini M5 Pro More Expensive Than The M6?

    Seattle Seahawks: Reigning Super Bowl champions to be sold in record $9.6bn deal

    Seattle Seahawks: Reigning Super Bowl champions to be sold in record $9.6bn deal

    New Mexico farmers, residents fear data center's impact on health, bills, jobs

    New Mexico farmers, residents fear data center's impact on health, bills, jobs